Ovarian reserve after treatment with alkylating agents during childhood

Human Reproduction

Volumn 30, Issue 6, 2015, Pages 1437-1446

  Thomas Teinturier, Cécile ^a,b   Allodji, Rodrigue Sétchéou ^b   Svetlova, Ekaterina ^b   Frey, Marie Alix ^b   Oberlin, Odile ^b   Millischer, Anne Elodie ^c   Epelboin, Sylvie ^d   Decanter, Christine ^e   Pacquement, Helene ^f   Tabone, Marie Dominique ^g   Sudour Bonnange, Helene ^h   Baruchel, André ⁱ   Lahlou, Najiba ^j   De Vathaire, Florent ^b,k  

^a BICÊTRE HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d BICHAT HOSPITAL   (France)

^e UNIV LILLE   (France)

^f INSTITUT CURIE   (France)

^g ARMAND TROUSSEAU HOSPITAL   (France)

^h CENTRE OSCAR LAMBRET   (France)

ⁱ HÔPITAL ROBERT DEBRÉ   (France)

^j Institut Cochin   (France)

^k UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

AMH; chemotherapy; childhood cancer survivors; hodgkin lymphoma; ovarian reserve

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; ESTRADIOL; FOLLITROPIN; IFOSFAMIDE; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; ORAL CONTRACEPTIVE AGENT; PROCARBAZINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FEMALE GENITAL TRACT PARAMETERS; FOLLICULAR PHASE; FOLLOW UP; HODGKIN DISEASE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; ORAL CONTRACEPTIVE USE; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVARIAN RESERVE; OVARIAN SURFACE AREA; PROSPECTIVE STUDY; REPRODUCTIVE TOXICITY; SOFT TISSUE SARCOMA; SURFACE AREA; BLOOD; DRUG EFFECTS; ECHOGRAPHY; OVARY; STATISTICAL MODEL; SURVIVOR;

ADOLESCENT; ADULT; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS, ALKYLATING; CROSS-SECTIONAL STUDIES; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HODGKIN DISEASE; HUMANS; LINEAR MODELS; LUTEINIZING HORMONE; OVARIAN RESERVE; OVARY; PROCARBAZINE; PROSPECTIVE STUDIES; SURVIVORS;

EID: 84939627609     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dev060     Document Type: Article

References (30)

1. Bath LE,Wallace WHB, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003;18:2368-2374.
2. Bentzen JG, Forman JL, Pinborg A, Lidegaard O, Larsen EC, Friis-Hansen L, Johannsen TH, Nyboe Andersen A. Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception. Reprod Biomed Online 2012;25:612-619.
3. Byrne J, Fears TR, Gail MH, Pee D, Connelly RC, Austin DF, Holmes GF, Holmes FF, Latourette HB, Meigs JW et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788-793.
4. Charpentier AM, Lee Chong A, Gingras-hill G, Ahmed S, Cigsar C, Gupta AA, Greenblatt E, Hodgson DC. Anti-Mullerian hormone screening to assess ovarian reserve among female survivors of childhood cancer. J Cancer Surviv 2014;8:548-554.
5. Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, Robison LL, Sklar CA. Acute ovarian failure in the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2006;91:1723-1728.
6. Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. Am J Epidemiol 1999;150:245-254.
7. CohenBL, KatzM. Further studies on pituitary andovarian function inwomen receiving hormonal contraception. Contraception 1981;24:159-172.
8. Couto-SilvaAC,Trivin C, Thibaud E, Esperou H, Michon J, Brauner R. Factors affecting gonadal function after bone marrow transplantation during childhood. Bone Marrow Transplant 2001;28:67-75.
9. Dewailly D, Pigny P, Soudan B, Catteau-Jonard S, Decanter C, Poncelet E, Duhamel A. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicule number and serum anti-Mullerian hormone concentrations aggregate with markers of hyperandrogenism. J Clin Endocrinol Metab 2010;95:4399-4405.
10. Dillon KE, Sammel MD, Ginsberg JP, Lechtenberg L, Prewitt M, Gracia CR. Pregnancy after cancer: results from a prospective cohort study of cancer survivors. Pediatr Blood Cancer 2013;60:2001-2006.
11. El-Shalakany AH, Ali MS, Abdelmaksoud AA, El-Ghany SA, Hasan EA. Ovarian function in female survivors of childhood malignancies. Pediatric Hematol Oncol 2013;30:328-335.
12. GattaG, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, Dimitrova N, Jakab Z, Kaatsch P, Lacour B et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-A population based study. Lancet Oncol 2014;15:35-47.
13. Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, Vance A, Ginsberg JP. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012;97:134-140.
14. Kelsey TW, Dodwell SK, Wilkinson AG, Greve T, Andersen CY, Anderson RA, Wallace WHB. Ovarian volume throughout life: a validated normative model. PLoS ONE 2013;8:e71465.
15. Krawczuk-Rybak M, Leszczynska E, Poznanska M, Zelazowska-Rutkowska B, Wysocka J. Anti-Mullerian hormone as a sensitive marker of ovarian function in young cancer survivors. Int J Endocrinol 2013;2013:125080.
16. Kristensen SL, Ramlau-Hansen CH, AndersenCY, Ernst E, Olsen SF, Bone JP, Vested A, Toft G. The association between circulating levels of antimullerian hormone and follicular number, androgens, and menstrual cycle characteristics in young women. Fertil Steril 2012;97:779-785.
17. Larsen EC, Muller J, Rechnitzer C, Schmiegelow K, Andersen AN. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH,10 IU/l. Hum Reprod 2003; 18:417-422a.
18. Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long-term survivors of radiation-and chemotherapytreated childhood cancer. J Clin Endocrinol Metab 2003;88:5307-5314b.
19. Ledger WL. Clinical utility of measurement of anti-Mullerian hormone in reproductive endocrinology. J Clin Endocrinol Metab 2010;95:5144-5154.
20. Lie Fong S, Laven JSE, Hakvoort-Cammel FGAJ, Schipper I, Visser JA, Themmen APN, de Jong FH, van den Heuvel-Eibrink MM. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod 2009;24:982-990.
21. Loh JS, Maheshwari A. Anti-Mullerian hormone-is it a crystal ball for predicting ovarian ageing? Human Reprod 2011;26:2925-2932.
22. Lunsford AJ, Whelan K, McCormick K, McLaren JF. Antimullerian hormone as a measure of reproductive function in female childhood cancer survivors. Fertil Steril 2014;101:227-231.
23. Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A. Anti-Mullerian hormone: clairvoyance or crystal clear? Human Reprod 2012;27:631-636.
24. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, RoccaWA. Premature menopause or early menopause: long term health consequences. Maturitas 2010;65:161-166.
25. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, Mulder J, Green D, Nicholson HS, Yasui Y. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Institute 2006;98:890-896.
26. Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 1998;22:989-994.
27. Thomas-Teinturier C, El Fayech C, Oberlin O, Pacquement H, Haddy N, Labbe M, Veres C, Guibout C, Diallo I, De Vathaire F. Age at menopause and its influencing factors in a cohort of survivors of childhood cancer: earlier but rarely premature. Hum Reprod 2013;28:488-495.
28. Van Beek RD, Van den Heuvel-Eibrink MM, Laven JSE, de Jong FH, Themmen APN, Hakvoort-Cammel FG, van den Bos C, van den Berg H, Pieters R, de Muinck Keizer-Schrama SMPF. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007;92:3869-3874.
29. Van den Berg MH, van Dulmen-den Broeder E, Overbeek A, Twisk JWR, Schats R, van Leeuwen FE, Kaspers GJ, Lambalk CB. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Human Reprod 2010;25:1520-1527.
30. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer 1983;52:988-993.